# CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. is a company headquartered in Newark, CA, United States.

## Company overview

- **Legal name:** CymaBay Therapeutics, Inc.
- **Former names in filing history:** METABOLEX, INC. (2009-07-21 to 2009-11-10); METABOLEX INC (2002-02-19 to 2009-03-05)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Newark, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001042074

## About

CymaBay Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001042074, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-02-28, it reported annual revenue of USD 31,073,000; net income of USD -105,370,000; total assets of USD 434,686,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $31.1M (USD 31,073,000)
- **Net income:** -$105.4M (USD -105,370,000)
- **Total assets:** $434.7M (USD 434,686,000)
- **Cash and equivalents:** $206.5M (USD 206,535,000)
- **Operating cash flow:** -$72.5M (USD -72,531,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$106.0M (USD -106,001,000)
- **Total assets:** $141.9M (USD 141,852,000)
- **Cash and equivalents:** $20.3M (USD 20,291,000)
- **Operating cash flow:** -$84.1M (USD -84,080,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$90.0M (USD -89,998,000)
- **Total assets:** $202.3M (USD 202,318,000)
- **Cash and equivalents:** $125.8M (USD 125,806,000)
- **Operating cash flow:** -$69.4M (USD -69,431,000)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2020 (period ended 2020-12-31)

- **Net income:** -$51.0M (USD -50,986,000)
- **Total assets:** $153.8M (USD 153,825,000)
- **Cash and equivalents:** $28.2M (USD 28,193,000)
- **Operating cash flow:** -$44.7M (USD -44,725,000)

## Recent SEC filings

- Form 8-K — filed 2024-03-22 — period 2024-03-22 — 8-K
- Form 8-K — filed 2024-03-20 — period 2024-03-18 — 8-K
- Form 10-K — filed 2024-02-28 — period 2023-12-31 — 10-K
- Form SC 13G — filed 2024-02-14 — JHG PLC OWNS >5%
- Form SC 13G — filed 2024-02-13 — SCHEDULE 13G
- Form 8-K — filed 2024-02-12 — period 2024-02-11 — 8-K
- Form 8-K — filed 2024-01-26 — period 2024-01-24 — 8-K
- Form SC 13G — filed 2024-01-25
- Form 8-K — filed 2023-12-21 — period 2023-12-19 — 8-K
- Form 8-K — filed 2023-12-13 — period 2023-12-11 — 8-K
- Form 10-Q — filed 2023-11-07 — period 2023-09-30 — 10-Q
- Form SC 13G — filed 2023-09-22 — SC 13G

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/cymabay-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology